Advertisement
DMRA vs NERV
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DMRA is a Buy and NERV is a Hold.
DMRA's RSI Oscillator recovers from oversold territory
The RSI Indicator for DMRA moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 27 of the 28 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 65 cases where DMRA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on DMRA as a result. In 77 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for DMRA just turned positive on October 07, 2026. Looking at past instances where DMRA's MACD turned positive, the stock continued to rise in 43 of 47 cases over the following month. The odds of a continued upward trend are 90%.
Following a +11.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where DMRA advanced for three days, in 205 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
DMRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for DMRA moved below the 200-day moving average on October 15, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DMRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for DMRA entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.443) is normal, around the industry mean (2.988). DMRA has a moderately low P/E Ratio (-82.808) as compared to the industry average of (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 43 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating steady price growth. DMRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
NERV sees MACD Histogram crosses below signal line
NERV saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 12, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 40 instances where the indicator turned negative. In 35 of the 40 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NERV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for NERV entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for NERV's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
Following a +4.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where NERV advanced for three days, in 193 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
NERV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.535) is normal, around the industry mean (2.988). P/E Ratio (-0.066) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.160) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. NERV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NERV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
DMRA | NERV | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 77 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 2 Undervalued | 41 Fair valued | |
PROFIT vs RISK RATING 1..100 | 43 | 100 | |
SMR RATING 1..100 | 99 | 100 | |
PRICE GROWTH RATING 1..100 | 53 | 87 | |
P/E GROWTH RATING 1..100 | 15 | 97 | |
SEASONALITY SCORE 1..100 | 39 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DMRA's Valuation (2) in the null industry is somewhat better than the same rating for NERV (41) in the Biotechnology industry. This means that DMRA’s stock grew somewhat faster than NERV’s over the last 12 months.
DMRA's Profit vs Risk Rating (43) in the null industry is somewhat better than the same rating for NERV (100) in the Biotechnology industry. This means that DMRA’s stock grew somewhat faster than NERV’s over the last 12 months.
DMRA's SMR Rating (99) in the null industry is in the same range as NERV (100) in the Biotechnology industry. This means that DMRA’s stock grew similarly to NERV’s over the last 12 months.
DMRA's Price Growth Rating (53) in the null industry is somewhat better than the same rating for NERV (87) in the Biotechnology industry. This means that DMRA’s stock grew somewhat faster than NERV’s over the last 12 months.
DMRA's P/E Growth Rating (15) in the null industry is significantly better than the same rating for NERV (97) in the Biotechnology industry. This means that DMRA’s stock grew significantly faster than NERV’s over the last 12 months.
| DMRA | NERV | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| Stochastic ODDS (%) | 2 days ago 89% | N/A |
| Momentum ODDS (%) | 2 days ago 88% | N/A |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 88% |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 86% |
| Advances ODDS (%) | 2 days ago 86% | 17 days ago 80% |
| Declines ODDS (%) | 9 days ago 86% | 4 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 86% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 82% | 2 days ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DMRA’s FA Score shows that 2 FA rating(s) are green while NERV’s FA Score has 0 green FA rating(s).
- DMRA’s FA Score: 2 green, 3 red.
- NERV’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DMRA’s TA Score shows that 6 TA indicator(s) are bullish while NERV’s TA Score has 3 bullish TA indicator(s).
- DMRA’s TA Score: 6 bullish, 3 bearish.
- NERV’s TA Score: 3 bullish, 3 bearish.
Price Growth
DMRA (@Biotechnology) experienced а +16.82% price change this week, while NERV (@Biotechnology) price change was +1.70% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
Reported Earning Dates
DMRA is expected to report earnings on Nov 05, 2026.
NERV is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
DMRA and
Correlation & Price change
A.I.dvisor indicates that over the last year, DMRA has been closely correlated with COGT. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if DMRA jumps, then COGT could also see price increases.
| Ticker / NAME | Correlation To DMRA | 1D Price Change % | ||
|---|---|---|---|---|
| DMRA | 100% | +4.16% | ||
| COGT - DMRA | 74% Closely correlated | +0.61% | ||
| NERV - DMRA | 45% Loosely correlated | -5.53% | ||
| INBX - DMRA | 44% Loosely correlated | +3.03% | ||
| RANI - DMRA | 44% Loosely correlated | -7.32% | ||
| GNTA - DMRA | 38% Loosely correlated | +4.92% | ||
More | ||||